Closing the “Other Doors”: Why Seyfried’s Metabolic Model Is Harder to Translate Than It Sounds
And why I posted a more 'doable' cocktail
Beyond the Metro Map
Jane McLelland’s private research notes & weekly updates on published metabolic & off-label drug studies
Live Last read · last published · next check
Latest posts
When Tumours Make Their Own Ketones: Where I Agree With Dr Nasha
And Where the Science Still Demands Caution
Beyond Fenbendazole and Ivermectin: Why We Need Better Conversations About Off‑Label Cancer Treatments
Why we need better Conversations about Off Label Cancer Treatments
When the Tumour Makes Its Own Ketones
The cancers that use ketones to drive their growth.
The Seven-Lever Metabolic Stack - What to Do When Keto Is Not the Answer
Part 1B of the 'Doable Cocktail' series. The four-question decision logic, the seven-lever metabolic stack, and why coordinated cocktails outperform any single dietary intervention.
When Keto Works and When It Doesn’t - A Cancer-by-Cancer Guide
Part 1A of the ‘Doable’ Cocktail series. A disease-by-disease breakdown of which cancers genuinely need strict ketogenic diet, which cancers it actively harms
Healthy Cells Don’t Die. Here’s Why.
Why blocking OXPHOS in cancer cells doesn't kill you
How to Starve Hormone-Positive (ER+) Breast Cancer on Tamoxifen - A Refresh
Fasting, the cocktail, and the metabolic-flexibility step almost everyone misses
Cholesterol triple threat: This Is What the Cocktail Looks Like
How statin, dipyridamole, and evolocumab form the one lipid circuit cancer cannot route around
The Most Overlooked Drug on the Metro Map
And why your statin protocol is incomplete without it